Lori Anne Kunkel is Director at Loxo Oncology, Inc. (LOXO). They have made 7 open-market trades across 1 company since 2017, most recently 2026-07-06.
CIK 0001536368
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ELVN | SELL · 10b5-1 | 2026-07-06 | 2026-07-08 | $50.49 | $505K | +1.4% | +18.5% | -16.8% |
| ELVN | SELL · 10b5-1 | 2026-06-05 | 2026-06-09 | $34.54 | $345K | +27.1% | +44.5% | +64.1% |
| CRIS | SELL · 10b5-1 | 2019-01-23 | 2019-01-25 | $1.05 | $16K | -7.2% | -11.2% | +42.4% |
| LOXO | SELL | 2018-10-01 | 2018-10-03 | $170.37 | $852K | -5.3% | +1.6% | -16.5% |
| LOXO | SELL | 2018-06-15 | 2018-06-18 | $176.85 | $1.2M | -3.7% | +1.3% | -11.9% |
| LOXO | SELL | 2018-06-14 | 2018-06-18 | $179.84 | $14.1M | -3.7% | +1.3% | -11.9% |
| LOXO | SELL | 2018-06-14 | 2018-06-18 | $180.47 | $5.8M | -3.7% | +1.3% | -11.9% |
| LOXO | SELL | 2018-04-20 | 2018-04-24 | $132.57 | $782K | -6.6% | +30.7% | +36.4% |
| LOXO | SELL | 2017-11-02 | 2017-11-06 | $85.02 | $663K | -14.9% | -11.9% | +6.9% |
| LOXO | SELL | 2017-08-22 | 2017-08-23 | $75.17 | $752K | +3.2% | +13.4% | -1.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.